title: Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance - authors' reply.
authors.affiliation: Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Disease, Centers for Disease Control and Prevention (CDC), Anchorage, AK, USA.
authors.forename: P P
authors.identifier: 0000-0002-8600-0348
authors.initials: PP
authors.lastname: Gounder
authors.affiliation: Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Disease, Centers for Disease Control and Prevention (CDC), Anchorage, AK, USA.
authors.forename: E M
authors.initials: EM
authors.lastname: Mosites
authors.affiliation: Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Disease, Centers for Disease Control and Prevention (CDC), Anchorage, AK, USA.|Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
authors.forename: B J
authors.initials: BJ
authors.lastname: McMahon
mesh_terms: D006528:Carcinoma, Hepatocellular; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006513:Hepatitis B e Antigens; D006515:Hepatitis B virus / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000276:immunology; D006801:Humans; D008113:Liver Neoplasms
chemical_list: D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens